A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept

Table 2

Clinical characteristics of all studies included in the meta-analysis.

Authors	Mean age (years)	Duration of disease (months)	Nb of injections prior to conversion	Time between last anti-VEGF and conversion	Mean time of follow-up (months)	Mean number of aflibercept injections	Treatment regimen
Kumar [24]	79; (IQR 72–84)	44.7; (IQR 24–76)	28.6; (IQR 10–47)	34.4 days (IQR 32–37)	6	5.6 (NS)	Loading then PRN
Bakall [25]	79; (range 60–88)	NS	25.6 (6–74)	NS	6	5.2 (4–6)	Loading then PRN
Gharbiya [26]	70.1; (range 60–86)	41.3 (15–58)	34.4 (15–50)	5.1 weeks (range 4–6)	6	4.5 (3–6)	Loading then PRN
Messenger [27]	80.3; (range 59–96)	NS	21.4 (4–60)	NS	6, 12	7.2 (1–12) for 12; months; NS at 6 months	Loading then PRN
Wykoff [28]	77.8; (range 55–95)	NS	42 (19–67)	33 days; (range 28–68)	6	5.6 (4–6)	Loading then PRN
Chang [29]	77.8 (NS)	40	34.94	NS	6	NS	Loading then bimonthly
Singh [30]	78 (NS)	14	9.62 (3–23)	50 days; (range 21–91)	6	NS	Loading then bimonthly